![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/spacer.gif)
polyvalent antigen-KLH conjugate vaccine A multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration, polyvalent antigen-KLH conjugate vaccine may induce production of IgG and IgM antibodies and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these TAAs, resulting in tumor cell death and tumor growth inhibition. Globo H (globo H hexasaccharide 1); GM2 ganglioside; Tn-MUC1 (human tumor-associated epithelial mucin 1 carrying the tumor-specific glycan Tn); TF (Thompson-Friedreich); and sTn (sialyl-Tn) are overexpressed in a variety of cancer cells. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition of antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509192815im_/http://www.cancer.gov/images/spacer.gif) |